XRTX
Closed
Xortx Therapeutics Inc
1.82
-0.35 (-16.13%)
Last Update: 17 Oct 2024 23:07:00
Yesterday: 2.17
Day's Range: 1.81 - 2.085
Send
sign up or login to leave a comment!
When Written:
0.67
XORTX Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative therapies for kidney disease. The company's lead product candidate is XRx-101, a small molecule inhibitor of serum uric acid (sUA) that is being developed for the treatment of hyperuricemia and kidney disease. XRx-101 has completed a Phase 2 clinical trial and is currently in Phase 2b clinical development. XORTX Therapeutics also has a pipeline of other product candidates, including XRx-221, which is being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company is headquartered in Calgary, Alberta, Canada.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.67
XORTX Therapeutics Inc. is a biopharmaceutical company that focuses on developing drugs for the treatment of kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD) and diabetic nephropathy. The company's lead product candidate, XRx-101, is a proprietary formulation of oxypurinol, which is being developed for the treatment of ADPKD. XRx-101 has been granted orphan drug designation by the US FDA and the European Medicines Agency. The company is also developing XRx-008 for the treatment of diabetic nephropathy. XORTX Therapeutics Inc. is headquartered in Calgary, Alberta, Canada, and is listed on the TSX Venture Exchange under the ticker symbol XRX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!